ZYDUSLIFENSEZydus Lifesciences LimitedMinimalNeutral
Announced Fri, 10 Apr · 11:41 IST

Zydus Lifesciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.2%1-day move
₹901.00
prior close
₹910.60
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1-0.1-0.0-0.0+2.2+3.9+4.2+4.9+3.8+3.0+1.6+6.6+21.8+27.7
Up moveDown movePending
AI summary

The entire Zydus promoter group, comprising 31+ entities and individuals including Pankaj Patel (Chairman), Sharvil Patel, various family trusts, HUFs, and related companies, has filed declarations confirming no encumbrances (pledges, liens, or charges) were placed on their equity shares during FY2026 ending March 31, 2026. This is a mandatory year-end compliance filing under SEBI SAST Regulations. All declarations were digitally signed and submitted to BSE and NSE on April 1-2, 2026. Some entities explicitly stated they hold no shares at all, while others confirmed their existing shareholdings remain free of any encumbrances.

Likely market impact

Positive signal for shareholders. The absence of encumbrances indicates promoters have not pledged their shares for loans or other obligations, reducing risk of forced sell-offs. This reflects promoter confidence in the company's financial health and their commitment to maintaining control without leveraging shares.